G. Tsokos, Systemic Lupus Erythematosus, New England Journal of Medicine, vol.365, issue.22, pp.2110-2131, 2011.
DOI : 10.1056/NEJMra1100359

B. Griffiths, M. Mosca, and C. Gordon, Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices, Best Practice & Research Clinical Rheumatology, vol.19, issue.5, pp.685-708, 2005.
DOI : 10.1016/j.berh.2005.03.010

D. Kuypers, L. Meur, Y. Cantarovich, M. Tredger, M. Tett et al., Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation, Clinical Journal of the American Society of Nephrology, vol.5, issue.2, pp.341-58, 2010.
DOI : 10.2215/CJN.07111009

P. Westeel, B. Hurault-de-ligny, L. Rostaing, E. Thervet, J. Szelag et al., Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation, Am J Transplant, vol.7, pp.2496-503, 2007.

P. Lechat, Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies, Clin Pharmacokinet, vol.47, pp.277-84, 2008.

S. Tett, F. Saint-marcoux, C. Staatz, M. Brunet, A. Vinks et al., Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure, Transplantation Reviews, vol.25, issue.2, pp.47-57, 2011.
DOI : 10.1016/j.trre.2010.06.001

URL : https://hal.archives-ouvertes.fr/inserm-00926489

L. Guellec, C. Marquet, and P. , A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil, Clin Pharmacokinet, vol.44, issue.10, pp.837-884, 2005.

P. Marquet, Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods, Ther Drug Monit, vol.27, issue.11, pp.354-61, 2005.

P. Marquet, Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation, Clin Pharmacokinet, vol.48, pp.667-75, 2009.
URL : https://hal.archives-ouvertes.fr/inserm-00377174

J. Landis and G. Koch, The Measurement of Observer Agreement for Categorical Data, Biometrics, vol.33, issue.1
DOI : 10.2307/2529310

Y. See, Y. Uziel, M. Mukamel, P. Riley, F. Zulian et al., The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set, Arthritis Rheum, vol.52, pp.2854-64, 2005.

I. Neumann, H. Fuhrmann, I. Fang, A. Jaeger, P. Bayer et al., Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil, Nephrology Dialysis Transplantation, vol.23, issue.11, pp.3514-3534, 2008.
DOI : 10.1093/ndt/gfn360

C. Sherwin, A. Sagcal-gironella, T. Fukuda, H. Brunner, and A. Vinks, Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus, British Journal of Clinical Pharmacology, vol.49, issue.5, pp.727-767, 2012.
DOI : 10.1111/j.1365-2125.2011.04140.x

P. Bonate, A Brief Introduction to Monte Carlo Simulation, Clinical Pharmacokinetics, vol.17, issue.1, pp.15-22, 2001.
DOI : 10.2165/00003088-200140010-00002

C. Brentano, J. Piette, and Z. Amoura, Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil, Arthritis Rheum, vol.62, pp.2047-54, 2010.

M. Klein-gitelman, A. Vinks, and H. Brunner, Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus, Semin Arthritis Rheum, vol.40, pp.307-320, 2011.

C. Staatz and S. Tett, Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients, Clinical Pharmacokinetics, vol.18, issue.2, pp.13-58, 2007.
DOI : 10.2165/00003088-200746010-00002

D. Kuypers, L. Meur, Y. Van-der-werf, M. Mamelok, R. Van-gelder et al., UGT1A9 -275T>A/- 2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients, Clin Pharmacol Ther, vol.86, issue.22, pp.319-346, 2009.